Skip to content

The Ensign Group ENSG Accrued litigation

Accrued litigation at other companies

Albemarle logo
AlbemarleALB
$10.42M
Altria Group logo
Altria GroupMO
$659M-2.8%
Altria Group logo
Altria GroupMO
$2.84B-6.4%
Willis Towers Watson logo
Willis Towers WatsonWTW
$120M-76.8%
Edwards Lifesciences logo
Edwards LifesciencesEW
$1.2B+0.6%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$0

Other financials

Income statement

See full
Revenue$1.4B+18.4%
Gross profit$293.4M+19.6%
Operating income$124.9M+23.2%
Net income$99.7M+24.2%
EPS (diluted)$1.67+21.9%

Balance sheet

See full
Cash & equivalents$539.5M+90.9%
Total debt$2.2B+11.7%
Total equity$2.4B+22.8%
Total assets$5.6B+17.9%

Cash flow

See full
Operating cash flow$100.2M+38.7%
CapEx$10.0M+27.8%
Free cash flow$90.2M+40.0%

Valuation

See full
Market cap$8.98B+57.5%
Enterprise value$10.69B+46.4%
P/E24.7×+6.3×
P/S1.7×+0.4×

Profitability

See full
Gross margin20.6%-0.1pp
Operating margin8.5%0.0pp
Net margin6.9%-0.1pp
FCF margin11%+2.6pp

Returns & leverage

See full
Return on equity16.9%-0.7pp
Debt / equity0.9×-0.1×
Current ratio1.6×+0.2×

Where this comes from

Reported directly by The Ensign Group in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserveCurrent.

The official record: The Ensign Group’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Ensign Group's accrued litigation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Ensign Group's accrued litigation?
The Ensign Group (ENSG) reported accrued litigation of $12M in Q1 2026.
What is the long-term trend for The Ensign Group's accrued litigation?
Over 2 years (2023 to 2025), The Ensign Group's accrued litigation has grown at a -51.8% compound annual growth rate (CAGR), from $51.73M to $12M.